Patents Assigned to Signal Pharmaceuticals LLC
  • Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith
    Patent number: 9795607
    Abstract: Provided herein are Pyrrolopyrimidine Compounds having the following structure: wherein R1, R2, R3, and L are as defined herein, compositions comprising an effective amount of a Pyrrolopyrimidine Compound, and methods for treating or preventing breast cancer, more particularly triple negative breast cancer, comprising administering an effective amount of such Pyrrolopyrimidine Compounds to a subject in need thereof.
    Type: Grant
    Filed: July 21, 2016
    Date of Patent: October 24, 2017
    Assignee: Signal Pharmaceuticals, LLC
    Inventors: Andrew Antony Calabrese, Brandon Jeffy, Dale Robinson, Dan Zhu, Dehua Huang, Jan Elsner, John Boylan, Lida Tehrani, Mark A. Nagy, Raj Kumar Raheja, Paul Erdman, Rama K. Narla, Roy L. Harris, Tam Minh Tran, Jennifer Riggs, Yuhong Ning, Shuichan Xu
  • Methods for treating cancer using TOR kinase inhibitor combination therapy
    Patent number: 9782427
    Abstract: Provided herein are methods for treating or preventing a cancer, comprising administering an effective amount of a TOR kinase inhibitor having the following formula (I): and an effective amount of a cytidine analog, such as 5-azacytidine, to a patient having a cancer.
    Type: Grant
    Filed: April 16, 2014
    Date of Patent: October 10, 2017
    Assignee: Signal Pharmaceuticals, LLC
    Inventor: Heather Raymon
  • Substituted diaminopyrimidyl compounds, compositions thereof, and methods of treatment therewith
    Patent number: 9783505
    Abstract: Provided herein are diaminopyrimidyl Compounds having the following structures: wherein X, L, R1, and R2 are as defined herein, compositions comprising an effective amount of a Diaminopyrimidyl Compound, and methods for treating or preventing PKC-theta-mediated disorders, or a condition treatable or preventable by inhibition of a kinase, for example, PKC-theta.
    Type: Grant
    Filed: August 19, 2016
    Date of Patent: October 10, 2017
    Assignee: Signal Pharmaceuticals, LLC
    Inventors: Patrick Papa, Brian Edwin Cathers, Andrew Antony Calabrese, Brandon Wade Whitefield, Brydon Bennett, Daniel Cashion, Deborah Mortensen, Dehua Huang, Eduardo Torres, Jason Parnes, John Sapienza, Joshua Hansen, Katerina Leftheris, Matthew Correa, Maria Mercedes Delgado, Raj K. Raheja, Sogole Bahmanyar, Sayee Hegde, Stephen Norris, Veronique Plantevin-Krenitsky
  • Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitors
    Patent number: 9771371
    Abstract: Provided herein are Heteroaryl Compounds having the following structure: wherein R1-R4 are as defined herein, compositions comprising an effective amount of a Heteroaryl Compound and methods for treating or preventing cancer, inflammatory conditions, immunological conditions, neurodegenerative diseases, diabetes, obesity, neurological disorders, age-related diseases, or cardiovascular conditions, comprising administering an effective amount of a Heteroaryl Compound to a patient in need thereof.
    Type: Grant
    Filed: October 5, 2015
    Date of Patent: September 26, 2017
    Assignee: Signal Pharmaceuticals, LLC
    Inventors: Jan Elsner, Roy L. Harris, Branden Gingsee Lee, Deborah Mortensen, Garrick K. Packard, Patrick Papa, Jason Parnes, Sophie Perrin-Ninkovic, Jennifer Riggs, John Sapienza, Graziella I. Shevlin, Lida Tehrani, Jingjing Zhao
  • Methods for treating cancer using TOR kinase inhibitor combination therapy comprising administering substituted pyrazino[2,3-b]pyrazines
    Patent number: 9737535
    Abstract: Provided herein are methods for treating or preventing a cancer, comprising administering an effective amount of a TOR kinase inhibitor and an effective amount a second active agent to a patient having a cancer, wherein the TOR kinase inhibitor is a compound of formula (I): and pharmaceutically acceptable salts, clathrates, solvates, stereoisomers, tautomers, metabolites, isotopologues and prodrugs thereof.
    Type: Grant
    Filed: April 15, 2015
    Date of Patent: August 22, 2017
    Assignee: Signal Pharmaceuticals, LLC
    Inventors: Kimberly Elizabeth Fultz, Tam Minh Tran, Shuichan Xu, Weiming Xu
  • Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith
    Patent number: 9737541
    Abstract: Provided herein are Aminopurine Compounds having the following structures: wherein R1, R2, and R3 are as defined herein, compositions comprising an effective amount of an Aminopurine Compound, and methods for treating or preventing a cancer, for example, melanoma.
    Type: Grant
    Filed: October 27, 2016
    Date of Patent: August 22, 2017
    Assignee: Signal Pharmaceuticals, LLC
    Inventors: Matthew Alexander, Sogole Bahmanyar, Joshua Hansen, Dehua Huang, Robert Hubbard, Brandon Jeffy, Jim Leisten, Mehran Moghaddam, Raj K. Raheja, Heather Raymon, Kimberly Schwarz, Marianne Sloss, Eduardo Torres, Tam Minh Tran, Shuichan Xu, JingJing Zhao, John Frederick Boylan
  • Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
    Patent number: 9725450
    Abstract: Provided herein are Aminopurine Compounds having the following structure: wherein R1, R2 and R3 are as defined herein, compositions comprising an effective amount of an Aminopurine Compound and methods for treating or preventing cancer, a cardiovascular disease, a renal disease, an autoimmune condition, an inflammatory condition, macular degeneration, ischemia-reperfusion injury, pain and related syndromes, disease-related wasting, an asbestos-related condition, pulmonary hypertension or a condition treatable or preventable by inhibition of the JNK pathway comprising administering an effective amount of an Aminopurine Compound to a patient in need thereof.
    Type: Grant
    Filed: October 21, 2015
    Date of Patent: August 8, 2017
    Assignee: Signal Pharmaceuticals, LLC
    Inventors: Steven Clareen, Veronique Plantevin-Krenitsky, Moorthy Palanki, Yoshitaka Satoh
  • Solid forms comprising 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one, and a coformer, compositions and methods of use thereof
    Patent number: 9718824
    Abstract: Provided herein are formulations, processes, solid forms and methods of use relating to 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one.
    Type: Grant
    Filed: April 15, 2015
    Date of Patent: August 1, 2017
    Assignee: Signal Pharmaceuticals, LLC
    Inventor: Kevin Klopfer
  • Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith
    Patent number: 9701643
    Abstract: Provided herein are Diaminopyrimidine Compounds having the following structures: wherein R1, R2, R3, and R4 are as defined herein, compositions comprising an effective amount of a Diaminopyrimidine Compound, and methods for treating or preventing liver fibrotic disorders or a condition treatable or preventable by inhibition of a JNK pathway.
    Type: Grant
    Filed: July 31, 2015
    Date of Patent: July 11, 2017
    Assignee: Signal Pharmaceuticals, LLC
    Inventors: Brydon L. Bennett, Mercedes Delgado, Jan Elsner, Paul Erdman, Robert Hilgraf, Laurie Ann LeBrun, Meg McCarrick, Mehran F. Moghaddam, Mark A. Nagy, Stephen Norris, David A. Paisner, William J. Romanow, Yoshitaka Satoh, Marianne Sloss, Jayashree Tikhe, Won Hyung Yoon
  • Treatment of cancer with dihydropyrazino-pyrazines
    Patent number: 9630966
    Abstract: Provided herein are methods for treating or preventing glioblastoma multiforme (GBM) characterized by O6-methylguanine-DNA methyltransferase (MGMT) expression and/or promoter methylation status, comprising administering an effective amount of a Dihydropyrazino-Pyrazine Compound to a patient having glioblastoma multiforme (GBM) characterized by O6-methylguanine-DNA methyltransferase (MGMT) expression and/or promoter methylation status.
    Type: Grant
    Filed: April 16, 2014
    Date of Patent: April 25, 2017
    Assignee: Signal Pharmaceuticals, LLC
    Inventors: Heather Raymon, Kristen Mae Hege
  • Methods of treating a cancer using substituted pyrrolopyrimidine compounds, compositions thereof
    Patent number: 9623028
    Abstract: Provided herein are methods for treating or preventing a cancer, in particular solid tumors and hematological cancers, comprising administering to a subject in need thereof an effective amount of a compound of formula (I):
    Type: Grant
    Filed: July 13, 2015
    Date of Patent: April 18, 2017
    Assignee: Signal Pharmaceuticals, LLC
    Inventors: Dan Zhu, John Boylan, Shuichan Xu, Jennifer Riggs, Tao Shi, Andrew Wurmser, David Mikolon, Gordafaried Deyanat-Yazdi
  • Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-YL)pyridin-3-YL)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino [2,3-B]pyrazin-2(1H)-one, a solid form thereof and methods of their use
    Patent number: 9604939
    Abstract: Provided herein are compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one, solid forms, isotopologs and metabolites thereof, and methods of their use for the treatment of a disease, disorder, or condition.
    Type: Grant
    Filed: May 28, 2014
    Date of Patent: March 28, 2017
    Assignee: Signal Pharmaceuticals, LLC
    Inventors: Marie Georges Beauchamps, Antonio Christian Ferretti, Juan Antonio Gamboa, Kevin Klopfer, William Edward Konnecke, Matthew Michael Kreilein, Anil Menon, Amanda Nicole Miklos, John Fitzgerald Traverse
  • Identification of LKB1 mutation as a predictive biomarker for sensitivity to TOR kinase inhibitors
    Patent number: 9555033
    Abstract: Provided herein are methods for treating and/or preventing a cancer or a tumor syndrome in a patient, comprising administering an effective amount of a TOR kinase inhibitor to a patient having cancer or a tumor syndrome, characterized by a LKB1 and/or AMPK gene or protein loss or mutation.
    Type: Grant
    Filed: February 3, 2011
    Date of Patent: January 31, 2017
    Assignee: Signal Pharmaceuticals, LLC
    Inventors: Rajesh Chopra, Yuhong Ning, Sabita Sankar, Shuichan Xu, Weiming Xu
  • Substituted diaminopyrimidyl compounds, compositions thereof, and methods of treatment therewith
    Patent number: 9556126
    Abstract: Provided herein are diaminopyrimidyl Compounds having the following structures: wherein X, L, R1, and R2 are as defined herein, compositions comprising an effective amount of a Diaminopyrimidyl Compound, and methods for treating or preventing PKC-theta-mediated disorders, or a condition treatable or preventable by inhibition of a kinase, for example, PKC-theta.
    Type: Grant
    Filed: December 19, 2014
    Date of Patent: January 31, 2017
    Assignee: Signal Pharmaceuticals, LLC
    Inventors: Patrick Papa, Brian Edwin Cathers, Andrew Antony Calabrese, Brandon Wade Whitefield, Brydon Bennett, Daniel Cashion, Deborah Mortensen, Dehua Huang, Eduardo Torres, Jason Parnes, John Sapienza, Joshua Hansen, Katerina Leftheris, Matthew Correa, Maria Mercedes Delgado, Raj K. Raheja, Sogole Bahmanyar, Sayee Hegde, Stephen Norris, Veronique Plantevin-Krenitsky
  • Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for tor kinase inhibitory activity
    Patent number: 9557338
    Abstract: Provided herein are methods for treating a cancer treatable by inhibition of phosphorylation of PRAS40, GSK3? or p70S6K1, comprising administering an effective amount of a TOR kinase inhibitor to a patient having a cancer treatable by inhibition of phosphorylation of PRAS40, GSK3? or p70S6K1.
    Type: Grant
    Filed: August 26, 2015
    Date of Patent: January 31, 2017
    Assignee: Signal Pharmaceuticals, LLC
    Inventors: Weiming Xu, Deborah Mortensen, Shuichan Xu, Kimberly Elizabeth Fultz
  • Methods for measurement of inhibition of c-Jun N-terminal kinase in skin
    Patent number: 9513297
    Abstract: Provided herein are methods for evaluating the effect of 2-(tert-butylamino)-4-((1R,3R,4R)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide or a pharmaceutically acceptable stereoisomer, tautomer, solid form, polymorph, salt, hydrate, clathrate, or solvate thereof in a patient with an assay based on UVB-irradiation and phosphorylated c-Jun expression. The analyzes allow for evaluation of dose-response and identification of patient populations who are sensitive to 2-(tert-butylamino)-4-((1R,3R,4R)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide or a pharmaceutically acceptable stereoisomer, tautomer, solid form, polymorph, salt, hydrate, clathrate, or solvate thereof.
    Type: Grant
    Filed: December 15, 2015
    Date of Patent: December 6, 2016
    Assignee: Signal Pharmaceuticals, LLC
    Inventors: Gerald Scott Barden Horan, Ying Ye
  • Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith
    Patent number: 9512124
    Abstract: Provided herein are Aminopurine Compounds having the following structures: wherein R1, R2, and R3 are as defined herein, compositions comprising an effective amount of an Aminopurine Compound, and methods for treating or preventing a cancer, for example, melanoma.
    Type: Grant
    Filed: October 5, 2015
    Date of Patent: December 6, 2016
    Assignee: Signal Pharmaceuticals, LLC
    Inventors: Matthew Alexander, Sogole Bahmanyar, Joshua Hansen, Dehua Huang, Robert Hubbard, Brandon Jeffy, Jim Leisten, Mehran Moghaddam, Raj K. Raheja, Heather Raymon, Kimberly Schwarz, Marianne Sloss, Eduardo Torres, Tam Minh Tran, Shuichan Xu, JingJing Zhao, John Frederick Boylan
  • Solid forms comprising 1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one and a coformer
    Patent number: 9512129
    Abstract: Provided herein are formulations, processes, solid forms and methods of use relating to 1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one.
    Type: Grant
    Filed: April 15, 2015
    Date of Patent: December 6, 2016
    Assignee: Signal Pharmaceuticals, LLC
    Inventor: Jeffrey Eckert
  • Treatment of cancer with dihydropyrazino-pyrazines
    Patent number: 9505764
    Abstract: Provided herein are methods for treating or preventing chronic lymphocytic leukemia, comprising administering an effective amount of a Dihydropyrazino-Pyrazine Compound to a patient having chronic lymphocytic leukemia.
    Type: Grant
    Filed: April 16, 2014
    Date of Patent: November 29, 2016
    Assignee: Signal Pharmaceuticals, LLC
    Inventors: Heather Raymon, Shuichan Xu, Antonia Lopez-Girona, Toshiya Tsuji, Kristen Mae Hege
  • Treatment of cancer with TOR kinase inhibitors
    Patent number: 9493466
    Abstract: Provided herein are methods for treating or preventing a solid tumor, non-Hodgkin lymphoma or multiple myeloma in a patient, comprising administering an effective amount of a TOR kinase inhibitor to a patient having a solid tumor, non-Hodgkin lymphoma or multiple myeloma.
    Type: Grant
    Filed: October 18, 2012
    Date of Patent: November 15, 2016
    Assignee: Signal Pharmaceuticals, LLC
    Inventors: Shuichan Xu, Kristen Mae Hege, Antonia Lopez-Girona, Heather Raymon, Rama K. Narla, Rajesh Chopra